Search

Your search keyword '"Dagmara Bialy"' showing total 3 results
Start Over Author "Dagmara Bialy" Journal nature communications
3 results on '"Dagmara Bialy"'

1. Creating resistance to avian influenza infection through genome editing of the ANP32 gene family

Author

Alewo Idoko-Akoh, Daniel H. Goldhill, Carol M. Sheppard, Dagmara Bialy, Jessica L. Quantrill, Ksenia Sukhova, Jonathan C. Brown, Samuel Richardson, Ciara Campbell, Lorna Taylor, Adrian Sherman, Salik Nazki, Jason S. Long, Michael A. Skinner, Holly Shelton, Helen M. Sang, Wendy S. Barclay, and Mike J. McGrew

Subjects
Science
Abstract

Abstract Chickens genetically resistant to avian influenza could prevent future outbreaks. In chickens, influenza A virus (IAV) relies on host protein ANP32A. Here we use CRISPR/Cas9 to generate homozygous gene edited (GE) chickens containing two ANP32A amino acid substitutions that prevent viral polymerase interaction. After IAV challenge, 9/10 edited chickens remain uninfected. Challenge with a higher dose, however, led to breakthrough infections. Breakthrough IAV virus contained IAV polymerase gene mutations that conferred adaptation to the edited chicken ANP32A. Unexpectedly, this virus also replicated in chicken embryos edited to remove the entire ANP32A gene and instead co-opted alternative ANP32 protein family members, chicken ANP32B and ANP32E. Additional genome editing for removal of ANP32B and ANP32E eliminated all viral growth in chicken cells. Our data illustrate a first proof of concept step to generate IAV-resistant chickens and show that multiple genetic modifications will be required to curtail viral escape.

Published
2023
Full Text
View/download PDF

2. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses

Author

Tiong Kit Tan, Pramila Rijal, Rolle Rahikainen, Anthony H. Keeble, Lisa Schimanski, Saira Hussain, Ruth Harvey, Jack W. P. Hayes, Jane C. Edwards, Rebecca K. McLean, Veronica Martini, Miriam Pedrera, Nazia Thakur, Carina Conceicao, Isabelle Dietrich, Holly Shelton, Anna Ludi, Ginette Wilsden, Clare Browning, Adrian K. Zagrajek, Dagmara Bialy, Sushant Bhat, Phoebe Stevenson-Leggett, Philippa Hollinghurst, Matthew Tully, Katy Moffat, Chris Chiu, Ryan Waters, Ashley Gray, Mehreen Azhar, Valerie Mioulet, Joseph Newman, Amin S. Asfor, Alison Burman, Sylvia Crossley, John A. Hammond, Elma Tchilian, Bryan Charleston, Dalan Bailey, Tobias J. Tuthill, Simon P. Graham, Helen M. E. Duyvesteyn, Tomas Malinauskas, Jiandong Huo, Julia A. Tree, Karen R. Buttigieg, Raymond J. Owens, Miles W. Carroll, Rodney S. Daniels, John W. McCauley, David I. Stuart, Kuan-Ying A. Huang, Mark Howarth, and Alain R. Townsend

Subjects
Science
Abstract

Vaccines for SARS-COV-2 are needed in the ongoing pandemic. Here the authors characterize a vaccine candidate that presents the receptor-binding domain (RBD) of SARS-CoV-2 spike protein on a synthetic VLP platform using SpyTag/SpyCatcher technology and show immunogenicity of a prime-boost regimen in mice and pigs.

Published
2021
Full Text
View/download PDF

3. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses

Author

Julia A. Tree, Tomas Malinauskas, Mark Howarth, Adrian K. Zagrajek, Veronica Martini, John W. McCauley, Ryan Waters, Jiandong Huo, Jane C. Edwards, Ginette Wilsden, Holly Shelton, Alison Burman, Anna B. Ludi, Rolle Rahikainen, Rod S. Daniels, Isabelle Dietrich, Huang K-Ya., David I. Stuart, Simon P. Graham, M. Pedrera, Valerie Mioulet, Raymond J. Owens, Christopher Chiu, Pramila Rijal, Nazia Thakur, Philippa Hollinghurst, Sushant Bhat, Hayes Jwp., Matthew Tully, Alain Townsend, Miles W. Carroll, Saira Hussain, Clare Browning, Tobias J. Tuthill, Tiong Kit Tan, Katy Moffat, Dagmara Bialy, Rebecca K. McLean, Elma Tchilian, Karen R. Buttigieg, Sylvia Crossley, Ashley R. Gray, Carina Conceicao, Joseph Newman, Phoebe Stevenson-Leggett, Ruth Harvey, Bryan Charleston, Mehreen Azhar, Dalan Bailey, Amin S. Asfor, Duyvesteyn Hme., Anthony H. Keeble, John A. Hammond, and Lisa Schimanski

Subjects
0301 basic medicine, Swine, viruses, General Physics and Astronomy, medicine.disease_cause, Antibodies, Viral, Epitope, Neutralization, Mice, 0302 clinical medicine, skin and connective tissue diseases, Coronavirus, chemistry.chemical_classification, Mice, Inbred BALB C, Multidisciplinary, biology, Immunogenicity, Antibodies, Monoclonal, virus diseases, Spike Glycoprotein, Coronavirus, Angiotensin-Converting Enzyme 2, Antibody, Protein vaccines, COVID-19 Vaccines, medicine.drug_class, Science, Monoclonal antibody, complex mixtures, Article, General Biochemistry, Genetics and Molecular Biology, Cell Line, 03 medical and health sciences, Immunity, medicine, Animals, Protein Interaction Domains and Motifs, Antibodies, Blocking, SARS-CoV-2, fungi, COVID-19, General Chemistry, Virology, Antibodies, Neutralizing, Mice, Inbred C57BL, 030104 developmental biology, chemistry, Viral infection, Preclinical research, biology.protein, Protein Multimerization, Glycoprotein, Peptides, 030217 neurology & neurosurgery
Abstract

There is need for effective and affordable vaccines against SARS-CoV-2 to tackle the ongoing pandemic. In this study, we describe a protein nanoparticle vaccine against SARS-CoV-2. The vaccine is based on the display of coronavirus spike glycoprotein receptor-binding domain (RBD) on a synthetic virus-like particle (VLP) platform, SpyCatcher003-mi3, using SpyTag/SpyCatcher technology. Low doses of RBD-SpyVLP in a prime-boost regimen induce a strong neutralising antibody response in mice and pigs that is superior to convalescent human sera. We evaluate antibody quality using ACE2 blocking and neutralisation of cell infection by pseudovirus or wild-type SARS-CoV-2. Using competition assays with a monoclonal antibody panel, we show that RBD-SpyVLP induces a polyclonal antibody response that recognises key epitopes on the RBD, reducing the likelihood of selecting neutralisation-escape mutants. Moreover, RBD-SpyVLP is thermostable and can be lyophilised without losing immunogenicity, to facilitate global distribution and reduce cold-chain dependence. The data suggests that RBD-SpyVLP provides strong potential to address clinical and logistic challenges of the COVID-19 pandemic., Vaccines for SARS-COV-2 are needed in the ongoing pandemic. Here the authors characterize a vaccine candidate that presents the receptor-binding domain (RBD) of SARS-CoV-2 spike protein on a synthetic VLP platform using SpyTag/SpyCatcher technology and show immunogenicity of a prime-boost regimen in mice and pigs.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results